July 12th 2024.
Researchers at the Indian Institute of Technology Delhi have developed a new nanoformulation that has shown promising results in pre-clinical trials for the treatment of deadly brain tumors. The most common and aggressive type of cancerous brain tumor in adults, glioblastoma, is known to be difficult to treat with current options like surgery, radiation, and chemotherapy.
Despite these available treatments, patients with glioblastoma typically only have a life expectancy of 12-18 months after diagnosis. This is why the team at IIT Delhi focused on developing a novel approach to enhance treatment efficacy and potentially offer new hope for improving outcomes in glioblastoma patients.
Their innovative solution, called Immunosomes, combines a CD40 agonist antibody with a small molecule inhibitor called RRX-001. Published in the journal Biomaterials, this approach aims to not only eradicate the tumor but also generate a strong immune response to fight against brain cancer.
In their pre-clinical trials, mice with glioblastoma treated with Immunosomes showed complete eradication of the tumor and remained tumor-free for at least three months. The treatment also produced a long-lasting immune memory that prevented future tumor recurrence without the need for further treatment.
In addition to its effectiveness against glioblastoma, Immunosomes also have the potential to reduce the toxicity associated with CD40 agonist antibody, which has been a major challenge for clinicians worldwide.
"We are highly motivated by these results and excited to translate them into human clinical trials with a wider range of glioblastoma patients," said Dr. Jayanta Bhattacharyya, an Associate Professor at the Centre for Biomedical Engineering at IIT Delhi.
This new nanoformulation offers hope for patients with glioblastoma, providing a potential solution to improve treatment efficacy and extend life expectancy. The team at IIT Delhi is eager to continue their research and bring this innovative treatment to human trials in the near future.
[This article has been trending online recently and has been generated with AI. Your feed is customized.]
